5 doctors weigh in on the promise, limitations of a closely watched multicancer blood test

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 19 Oct, 13:15 UTC

As a screening test from Grail moves closer to Food and Drug Administration approval, cancer experts share what encourages and concerns them most about Galleri.

science

Sources

• T25 doctors weigh in on the promise, limitations of a closely watched multicancer blood testBioPharma Dive / Healthcare Dive / MedTech Dive19 Oct, 13:15